RedHill Biopharma Reports 2017 Third Quarter Financial Results
RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017 In addition, an underwritten public offering of the Company’s American Depositary Shares (ADSs) is scheduled to be closed today, November 13, 2017, subject to customary terms and conditions, for aggregate net proceeds of approximately $20.6 […]